Evolus First Quarter 2025 Earnings: Misses Expectations

Simply Wall St · 05/09 12:42

Evolus (NASDAQ:EOLS) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$68.5m (up 16% from 1Q 2024).
  • Net loss: US$18.9m (loss widened by 44% from 1Q 2024).
  • US$0.30 loss per share (further deteriorated from US$0.22 loss in 1Q 2024).
earnings-and-revenue-growth
NasdaqGM:EOLS Earnings and Revenue Growth May 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Evolus Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 14% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Evolus (1 is potentially serious!) that you need to take into consideration.